Ayahuasca Research Report – 1984

Summary

The transcript presents a historical lecture by Dennis McKenna, introduced by Lorenzo, on the chemistry, ethnobotany, and pharmacology of two Amazonian hallucinogenic preparations: ayahuasca and Virola-based snuffs and pastes. The discussion frames the talk as an early public presentation of McKenna’s research from June 1984, likely tied to his thesis defense, and emphasizes its significance for both psychedelic science and traditional Amazonian medicine. The first major topic is ayahuasca, described as a brew made primarily from Banisteriopsis caapi combined with admixture plants such as Psychotria viridis in Peru and Diplopterys cabrerana in Colombia. McKenna explains that the brew’s psychoactivity depends on a combination of beta-carbolines from Banisteriopsis caapi—especially harmine, harmaline, and tetrahydroharmine—and tryptamines, especially DMT, from the admixture plants. He outlines the traditional preparation process, the role of the ayahuasquero, and the use of visions in diagnosing illness, identifying supernatural causes, and selecting remedies. He also notes that many medicinal plants are used in this system, suggesting a rich but underexplored source of pharmacologically active compounds. The second major topic is Virola, a genus in the nutmeg family used by Yanomamo and related groups to make hallucinogenic snuffs and orally active pastes. McKenna describes the resinous bark, the preparation of snuffs, and the different oral paste traditions found in regions of Peru and Venezuela. He emphasizes that these preparations are chemically more variable than ayahuasca, with different samples showing substantial differences in both quantity and type of alkaloids. The main compounds detected are tryptamines such as DMT and 5-methoxy-DMT, but beta-carbolines are usually absent or present only in trace amounts. A central scientific question in the talk is how these preparations become orally active. McKenna reviews the pharmacological rationale that DMT is not orally active unless monoamine oxidase is inhibited, and that beta-carbolines are potent reversible MAO inhibitors. He presents analytical work using HPLC, gas chromatography, thin-layer chromatography, and mass spectrometry to quantify alkaloids in multiple samples. For ayahuasca, he finds that the same major constituents appear consistently across samples, though their proportions vary depending on preparation methods, plant cultivars, and environmental factors. In contrast, Virola pastes and snuffs vary widely in composition, and their oral activity may require a different mechanism than the one proposed for ayahuasca. McKenna estimates that a typical 100 milliliter dose of ayahuasca contains enough DMT to fall within the known hallucinogenic range, while the beta-carbolines are present below their own hallucinogenic thresholds but in sufficient quantity to inhibit MAO and protect DMT from degradation. He concludes that ayahuasca’s psychoactivity is most plausibly explained by DMT made orally active through beta-carboline MAO inhibition. He also notes that the admixture plants Psychotria viridis and Diplopterys cabrerana are remarkably clean sources of DMT. The talk then turns to in vitro assays of MAO inhibition. McKenna reports that beta-carbolines are highly potent inhibitors, with harmine and harmaline among the most active compounds tested. Mixtures of beta-carbolines do not show strong synergy in vitro; their activity is largely intermediate between the most and least active components. Ayahuasca extracts themselves are also strong MAO inhibitors, even at high dilutions. By comparison, tryptamines are much weaker MAO inhibitors, though DMT shows some activity. Virola paste extracts, however, appear to be poor MAO inhibitors, and their limited activity seems to come mainly from tryptamines rather than beta-carbolines. McKenna then speculates on alternative mechanisms for Virola’s oral activity, including the possibility that other constituents such as lignans or methylenedioxyphenyl-containing compounds may inhibit microsomal enzymes and protect tryptamines from peripheral metabolism. He references research suggesting that DMT may be a poor direct substrate for MAO and may instead be metabolized through other pathways, including microsomal oxidation and conversion to N-methyltryptamine. This opens the possibility that enzyme inhibition beyond MAO could contribute to oral activity in some preparations. In the question-and-answer portion, the discussion broadens to diet, preparation variability, admixture plants, and the possibility that ayahuasca affects endogenous brain chemistry. McKenna and the host reflect on the diversity of ayahuasca experiences, the importance of traditional dietary restrictions, and the idea that beta-carbolines and tryptamines are also present in human biochemistry. He suggests that studying these plant compounds may illuminate broader questions about neurotransmission, schizophrenia, alcoholism, and the body’s own production and metabolism of DMT and related alkaloids. The transcript closes with Lorenzo reading a later passage from McKenna’s essay Ayahuasca and Human Destiny, which presents ayahuasca as a resilient plant intelligence that has spread beyond the Amazon and may outlast political and cultural systems. The closing reflection frames ayahuasca as a long-term teacher whose message humanity must learn to hear before it is too late.